![Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index | Scientific Reports Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-74055-3/MediaObjects/41598_2020_74055_Fig4_HTML.png)
Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index | Scientific Reports
![Diagnostics | Free Full-Text | Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer Diagnostics | Free Full-Text | Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer](https://pub.mdpi-res.com/diagnostics/diagnostics-11-01460/article_deploy/html/images/diagnostics-11-01460-g007.png?1628773983)
Diagnostics | Free Full-Text | Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
![Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | SpringerLink Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-06013-6/MediaObjects/10549_2020_6013_Fig1_HTML.png)
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | SpringerLink
![Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | SpringerLink Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-06013-6/MediaObjects/10549_2020_6013_Fig2_HTML.png)
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | SpringerLink
BC Cancer Protocol Summary for Neoadjuvant or Adjuvant Therapy for Breast Cancer using Anastrozole in Postmenopausal Women
Matteo Lambertini, MD PhD on Twitter: "The #CTS5 calculator to help predicting the risk of late distant recurrence in postmenopausal patients with #EstrogenReceptor-positive early #BreastCancer is freely available online: future possible application
![Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | springermedizin.de Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | springermedizin.de](https://media.springernature.com/lw400/springer-static/cover/journal/10549/186/1.jpg?as=jpg)
Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer | springermedizin.de
Pulsus Journal of Surgical Research Using CTS5 Calculator to predict the 5-10 risk of recurrence and to reduce the number of pat
![Frontiers | Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea Frontiers | Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea](https://www.frontiersin.org/files/MyHome%20Article%20Library/691277/691277_Thumb_400.jpg)
Frontiers | Validation of the Clinical Treatment Score Post–Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea
![Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index | Scientific Reports Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41598-020-74055-3/MediaObjects/41598_2020_74055_Fig3_HTML.png)
Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index | Scientific Reports
![CTS5 score partially validated for predicting late distant breast cancer recurrences | MDedge Hematology and Oncology CTS5 score partially validated for predicting late distant breast cancer recurrences | MDedge Hematology and Oncology](https://cdn.mdedge.com/files/s3fs-public/144138_Sestak_Ivana_web.jpg)
CTS5 score partially validated for predicting late distant breast cancer recurrences | MDedge Hematology and Oncology
![6-Quart ACDelco GM OE dexos1® Full Synthetic Oil Change and Tire Rotation | Bayway Cadillac Southwest Specials Houston, TX 6-Quart ACDelco GM OE dexos1® Full Synthetic Oil Change and Tire Rotation | Bayway Cadillac Southwest Specials Houston, TX](https://www.baywaycadillacsouthwest.com/inventoryphotos/12355/1g6dn5rw1p0131104/ip/6.jpg?bg-color=FFFFFF)